The Multiple Myeloma program at Mount Sinai is the largest of its kind in New York City and one of the largest in the country. We are known throughout the world as a leader in multiple myeloma patient care and translational research. With a high patient volume, including more than 400 new patients each year, we have developed a uniquely focused program. Multiple myeloma is a complex cancer. It is best treated by physicians who see myeloma patients day in and day out and who have an in-depth understanding of myeloma biology.
Our mission is to provide comprehensive, compassionate care for patients with multiple myeloma and related diseases and advance innovative research and personalized treatments that lead to cure.
We provide novel, precision-medicine therapies that offer the best chance for good outcomes with a high quality of life. Our physicians are internationally recognized in the diagnosis and treatment of multiple myeloma at all stages, including Monoclonal Gammopathy of Undertermined Significance (MGUS) and Smoldering Myeloma, as well as related diseases such as Waldenstrom Macroglobulinemia, Castleman Disease, and Amyloidosis.
We offer the highest quality of care targeted to your disease for the best possible outcome. You will benefit from our innovative research in genomics, epigenetics, and immunotherapy, and our ability to quickly translate new findings into effective treatments.